Novartis AG
NYSE:NVSDrug Manufacturers - General
-$3.38 today
- Market cap
- $293.13B
- Beta
- 0.49
- P/E (TTM)
- 20.7
- EPS (TTM)
- $7.06
- Dividend yield
- 3.13%
Volume 2.75M
Average 1.56M
NVS EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Novartis AGNYSE: NVS
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA declines year over year
Q2 FY2026 EBITDA of $5.94B fell 2.3% year over year, in line with the -2.0% change in trailing-twelve-month EBITDA. Sequentially, it rose 9.7% from the prior quarter. Over 3 fiscal years it compounded at +16.1% a year.
Context
- EBITDA amounted to 41.9% of revenue in FY2025, up 1.9 pp from a year earlier.
- EBITDA increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 12 analysts of $24.51B (+6.6%) for the fiscal year ending Dec 2026, a slowdown from the +11.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $5.94B+9.7% QoQ
- Last fiscal yearDec 2025
- $22.99B+11.0% YoY
- LTMJun 2026
- $22.26B-2.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -2.3% | +48.5% | +50.8 pp |
| 1 year | +11.0% | +6.6% | -4.3 pp |
| 3-year CAGR | +16.1% | +6.8% | -9.3 pp |
| 5-year CAGR | +7.0% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 22.99B USD
- Year-over-year change
- +11.0%
- 4-year CAGR
- -7.1%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 22.99B | +11.0% |
| FY2024 | 2024-12-31 | 20.72B | +13.5% |
| FY2023 | 2023-12-31 | 18.26B | +24.3% |
| FY2022 | 2022-12-31 | 14.68B | -52.5% |
| FY2021 | 2021-12-31 | 30.91B | — |
EBITDA vs competitors
How NVS compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -2.0% is the 7th highest of 11, against a peer median of +3.4%.
- EBITDA amounts to 40.0% of revenue for NVS, versus a peer median of 30.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | DKK 180.91B DKK | +4.7% | +26.8% | 54.9% | |
| LTM Sep 2026 | $30.81B USD | -22.1% | +15.6% | 31.0% | |
| LTM Sep 2026 | $24.15B USD | +88.7% | -10.0% | 36.6% | |
| LTM Jun 2026 | $22.26B USD | -2.0% | +16.1% | 40.0% | |
| LTM Sep 2026 | $21.37B USD | +18.6% | +29.7% | 34.4% | |
| LTM Jun 2026 | $16.82B USD | +11.6% | -7.5% | 34.2% | |
| LTM Jun 2026 | €14.77B EUR | +15.5% | -2.6% | 30.2% | |
| LTM Jun 2026 | $13.93B USD | -44.4% | +9.9% | 21.0% | |
| LTM Jun 2026 | $13.49B USD | -33.1% | -25.8% | 21.2% | |
| LTM Jun 2026 | £8.8B GBP | +2.2% | +6.5% | 26.5% | |
| LTM Jun 2026 | $1.33B USD | -87.8% | +15.3% | 4.4% | |
| Peer median (excluding NVS) | — | +3.4% | +8.2% | 30.6% | |
Competitors are the stored peer set for NVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 43.97B | 43.46B | 46.66B | 51.72B | 54.81B |
| Cost of Revenue | 11.74B | 11.58B | 12.47B | 12.83B | 13.69B |
| Gross Profit | 32.24B | 31.88B | 34.19B | 38.9B | 41.12B |
| Gross Margin | 73.3% | 73.4% | 73.3% | 75.2% | 75.0% |
| Research & Development | 8.64B | 9.17B | 11.37B | 10.02B | 10.74B |
| Selling, General & Admin | 12.83B | 12.19B | 12.52B | 12.57B | 13.31B |
| Operating Expenses | 22.18B | 23.93B | 24.42B | 24.35B | 24.05B |
| Depreciation & Amortization | 5.6B | 6.71B | 8.28B | 6.07B | 5.35B |
| EBITDA | 30.91B | 14.68B | 18.26B | 20.72B | 22.99B |
| EBITDA Margin | 70.3% | 33.8% | 39.1% | 40.1% | 41.9% |
| Operating Income | 10.06B | 7.95B | 9.77B | 14.54B | 17.07B |
| Operating Margin | 22.9% | 18.3% | 20.9% | 28.1% | 31.2% |
| Interest Income | 71M | 377.74M | 629.24M | 567.68M | 374.91M |
| Interest Expense | 905M | 834.62M | 876.12M | 1.04B | 1.19B |
| Other Income / Expenses | 14.47B | (769M) | (646M) | (904M) | (638.25M) |
| Income Before Tax | 24.53B | 7.18B | 9.12B | 13.64B | 16.44B |
| Pre-Tax Margin | 55.8% | 16.5% | 19.6% | 26.4% | 30.0% |
| Income Tax Expense | 1.63B | 1.13B | 551M | 1.7B | 2.4B |
| Net Income | 24.02B | 6.96B | 14.85B | 11.94B | 14.06B |
| Net Margin | 54.6% | 16.0% | 31.8% | 23.1% | 25.6% |
| EPS (Basic) | 10.71 | 3.19 | 7.15 | 5.92 | 7.25 |
| EPS (Diluted) | 10.63 | 3.17 | 7.10 | 5.87 | 7.19 |
| Weighted Avg Shares | 2.24B | 2.18B | 2.08B | 2.02B | 1.94B |
| Weighted Avg Shares (Diluted) | 2.26B | 2.2B | 2.09B | 2.04B | 1.96B |
Novartis AG
NYSE:NVS
Intrinsic Alpha fair value
Locked
Current Price
$155.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.